University of British Columbia

The University of British Columbia (UBC) is a public research university with major campuses in Vancouver and Kelowna, British Columbia, Canada. Established in 1908, it is one of Canada's largest universities. UBC is a globally recognized institution, consistently ranked among the top 40 universities worldwide. For the 2026/27 fiscal year, UBC's annual consolidated budget is projected to be $4.19 billion. In 2025, the university had an estimated 33,343 employees and a total student population of over 72,000 across both campuses.

UBC's primary operations involve providing post-secondary education through a wide range of undergraduate and graduate programs across various disciplines, including arts, sciences, engineering, medicine, and business management. Beyond teaching, UBC is a significant center for research, with an annual research budget of $936.40 million funding over 10,000 projects, leading to the spin-off of numerous companies. The university also engages in community services, operates museums, conference centers, and performing arts venues.

In terms of patent litigation, the University of British Columbia appears to be an operating company defending its intellectual property. The provided data shows UBC as a defendant in one tracked case and as a plaintiff in zero cases. This posture indicates that UBC is primarily a target in patent disputes, likely defending patents derived from its extensive research activities.

The sole tracked case involving the University of British Columbia is CaptION Health Inc. v. University of British Columbia, filed on August 15, 2025, before the Patent Trial and Appeal Board (PTAB). This case involves an inter partes review (IPR) challenge to UBC's U.S. Patent No. 10,751,029, which is directed to a computer-implemented method and system for analyzing ultrasound images using neural networks. The PTAB instituted trial in this proceeding on February 3, 2026. There is also mention of parallel district court litigation where a motion to stay pending IPR was denied without prejudice.